Key result
COVID-19 myocardial injury affects ~15% of patients, while suspected myocarditis remains rare and heterogeneously managed.
Why the study?
Myocardial injury is common in COVID-19 patients, but there is discrepancy in the literature regarding myocarditis as the underlying etiology and limited published data beyond anecdotal and case reports.
Provides clinicians with an early framework for recognizing, diagnosing (via POCUS, TTE, CMR, and EMB), and managing suspected COVID-19-associated myocarditis with supportive and guideline-directed heart failure care.
Answers are grounded in this paper and cite their sources.
Myocardial injury warrants monitoring in COVID-19; leaves open prospective trials to standardize diagnosis and therapy for rare suspected myocarditis.
COVID-19 has been declared a global pandemic by the World Health Organization and is responsible for hundreds of thousands of deaths worldwide. COVID-19 is caused by SARS-CoV-2, and common clinical symptoms include fever, cough, sore throat, headache, and fatigue. Myocardial injury is relatively common in patients with COVID-19, accounting for 7%-23% of cases, and is associated with a higher rate of morbidity and mortality. There is a discrepancy in the literature about myocarditis as the etiology of myocardial injury in patients with COVID-19; although many anecdotal reports of myocarditis have been noted, there are only a handful of case reports in the literature about myocarditis related to COVID-19. In this review we summarize the most up to date literature around the association between COVID-19 and myocarditis and provide clinicians a practical framework about the clinical manifestations, diagnostic tools, and treatment options currently available. Importantly, this review will heighten suspicion for myocarditis as an etiology of myocardial injury in COVID-19 patients, therefore improving clinical outcomes and encouraging shared clinical decision-making. This will also open the door for further research to build around this review. Emergent treatment options for COVID-19 are in clinical trials and might be of benefit to COVID-19 patients with myocarditis in addition to current guideline-based recommendations.
No takes yet. Share an insight, caveat, or question.
Pirzada et al. (2020) conducted a review in COVID-19 and myocarditis. Myocardial injury occurs in 7%-23% of COVID-19 patients, while clinically suspected myocarditis is a rare and heterogeneous sequela managed primarily with supportive and guideline-directed therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: